Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Prevention of vertebral fractures in osteoporosis: Mixed treatment comparison of bisphosphonate therapies
Current Medical Research and Opinion, 06/23/09
Jansen JP et al. - Data indicate that zoledronic acid provides a greater vertebral fracture risk reduction in postmenopausal women with osteoporosis than ibandronate, alendronate, or risedronate.
Methods- A comparison of the efficacy of bisphosphonates in prevention of vertebral fractures in postmenopausal women with osteoporosis
- 7 randomized placebo controlled trials investigating the effects of:
- Zoledronic acid (1 study)
- Alendronate (3 studies)
- Ibandronate (1 study), and
- Risedronate (2 studies)
- on fractures with a f/u of 3 yrs were identified
- Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison (MTC)
- Zoledronic acid shows the greatest reduction in vertebral fractures of all four bisphophonates compared
- It showed an OR of 0.28 vs placebo, an OR of 0.57 vs ibandronate, an OR of 0.54 vs alendronate, and OR of 0.49 vs risedronate
- Alendronate, ibandronate, and risedronate showed comparable vertebral fracture reductions
- Indirect comparisons using a conservative random effects model supported these findings
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Biphasic effects of hormone treatment on risk of cardiovascular disease
Sexuality, Reproduction & Menopause, 10/20/09
Sponsor
Article Search
Sponsor


See Latest Articles


